Packaging

ASTRAZENECA CLINICAL TRIALS GOES AUTOMATED WITH NEWMAN LABELLER

Wednesday 27. January 2010 - Leading pharmaceutical company and long time Newman Labelling customer AstraZeneca has purchased a Newman NV2 fully automatic, self-adhesive labelling system for its Clinical Trials Production Unit.

The new NV2 will be used by AstraZeneca as part of its ongoing initiative to
automate the Clinical Trials Assembly Process. It has been introduced following
the installation of a new label printing system which is able to print reel fed,
short edge leading labels. Up until now, labelling operations at the Clinical
Trials Production Unit were performed by hand, but automating the system makes
for a quicker, more accurate and ultimately more efficient process.

To enhance this automation further, the NV2 has been supplied by Newman with a
missing label detection system.

AstraZeneca has enjoyed a long term working relationship with Newman Labelling
over the past 20 years using a significant number and variety of Newman
machines. This latest installation comes on the back of this relationship and,
as always “The specification, purchase and installation has been smooth”
according to Steve Walker, Investigational Products at AstraZeneca.

The NV2 is a fully automatic, self-adhesive labeling system for cylindrical,
flat, square and oval containers. It is designed for maximum versatility,
offering the capability to label containers from 10mm to 150mm with minimal
change parts.

The NV2 is available exclusively from Newman Labelling Systems, a leading
manufacturer of labelling machines designed specifically for the pharmaceutical
industry, with a customer base that includes the world’s top ten pharmaceutical
companies. All purpose built systems are fully compliant with FDA cGMP
requirements and can be supplied with validation completed up to PQ.